Evofem Biosciences enters exchange agreements for Series F-1 Preferred Stock in connection with Aditxt merger

Evofem Biosciences, Inc.

Evofem exchanged certain rights and warrants with holders for 22,280 shares of new Series F-1 Convertible Preferred Stock.
The exchange agreements were executed on Dec 21, 2023, following the merger agreement with Aditxt signed on Dec 11, 2023.
Holders agreed to waive change of control redemption rights related to the merger in exchange for new rights and preferred stock.
The Series F-1 Preferred Stock will later be exchanged for Aditxt preferred stock prior to merger consummation.
The exchange was exempt from registration under Section 3(a)(9) of the Securities Act.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Evofem Biosciences, Inc. entered into Rights Exchange Agreement with Holders of previously issued Securities valued at Exchange of Original Rights for New Rights (effective 2023-12-21).

Action: entry
Counterparty: Holders of previously issued Securities
Value: Exchange of Original Rights for New Rights
Effective: 2023-12-21

Exact text from the filing

On December 21, 2023, Evofem Biosciences, Inc. (the “Company”) entered into the following agreements with holders (each a “Holder”) of certain of the Company’s previously issued Securities (as defined below) (i) a waiver and rights exchange agreement (the “Rights Exchange Agreements")

View on SEC.gov

Browse all material agreements →

Evofem Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-046163

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.